(Q33987817)

30 July 2017

title

Prolonged central mu-opioid receptor occupancy after single and repeated nalmefene dosing (English)

1 reference

30 July 2017

Sargo Aalto

3

0 references

Harry Scheinin

object named as

Harry Scheinin

10

0 references

Vesa Oikonen

object named as

Vesa Oikonen

8

0 references

Nora Hagelberg

2

object named as

Nora Hagelberg

1 reference

30 July 2017

Kimmo Ingman

1

1 reference

30 July 2017

Kjell Någren

4

1 reference

30 July 2017

Auni Juhakoski

5

1 reference

30 July 2017

Sakari Karhuvaara

6

1 reference

30 July 2017

Antero Kallio

7

1 reference

30 July 2017

Jarmo Hietala

9

1 reference

30 July 2017

language of work or name

English

0 references

publication date

1 December 2005

1 reference

30 July 2017

published in

Neuropsychopharmacology

1 reference

30 July 2017

volume

30

1 reference

30 July 2017

issue

12

1 reference

30 July 2017

page(s)

2245-2253

1 reference

A multi-site dose ranging study of nalmefene in the treatment of alcohol dependence

30 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300790

A 6-month controlled naltrexone study: combined effect with cognitive behavioral therapy in outpatient treatment of alcohol dependence

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300790

Mu-opioid receptor binding measured by [11C]carfentanil positron emission tomography is related to craving and mood in alcohol dependence

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300790

Effect of selective blockade of mu(1) or delta opioid receptors on reinstatement of alcohol-seeking behavior by drug-associated stimuli in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300790

The role of opioid-dopamine interactions in the induction and maintenance of ethanol consumption

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300790

Orally administered opioid antagonists reverse both mu and kappa opioid agonist delay of gastrointestinal transit in the guinea pig.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300790

Pharmacologic profile of NPC 168 (naltrexone phenyl oxime), a novel compound with activity at opioid receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300790

Nalmefene: safety and kinetics after single and multiple oral doses of a new opioid antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300790

Effects of naltrexone and nalmefene on subjective response to alcohol among non-treatment-seeking alcoholics and social drinkers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300790

Quantification of brain mu-opioid receptors with [11C]carfentanil: reference-tissue methods

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300790

Prolonged blockade of opioid effect with oral nalmefene

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300790

Lack of efficacy of naltrexone in the prevention of alcohol relapse: results from a German multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300790

Endogenous opioids and addiction to alcohol and other drugs of abuse

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300790

Parametric imaging of ligand-receptor binding in PET using a simplified reference region model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300790

Endogenous opioid systems and alcohol addiction

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300790

Ligand-receptor interactions as studied by PET: implications for drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300790

Central Opioid Receptors Differentially Regulate the Nalmefene-Induced Suppression of Ethanol- and Saccharin-Reinforced Behaviors in Alcohol-Preferring (P) Rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300790

Drugs of abuse: anatomy, pharmacology and function of reward pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300790

Naltrexone vs. nefazodone for treatment of alcohol dependence. A placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300790

Simplified reference tissue model for PET receptor studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300790

A double-blind, placebo-controlled pilot study to evaluate the efficacy and safety of oral nalmefene HCl for alcohol dependence

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300790

A double-blind, placebo-controlled study of oral nalmefene for alcohol dependence

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300790

Using [11C]diprenorphine to image opioid receptor occupancy by methadone in opioid addiction: clinical and preclinical studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300790

Naltrexone-induced nausea in patients treated for alcohol dependence: clinical predictors and evidence for opioid-mediated effects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300790

Initial and maintenance naltrexone treatment for alcohol dependence using primary care vs specialty care: a nested sequence of 3 randomized trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300790

Adverse effects of oral naltrexone: analysis of data from two clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300790

21 January 2018

Opioids and alcoholism

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300790

Rapid release of antipsychotic drugs from dopamine D2 receptors: an explanation for low receptor occupancy and early clinical relapse upon withdrawal of clozapine or quetiapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300790

Drugs to decrease alcohol drinking

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300790

Models and methods for derivation of in vivo neuroreceptor parameters with PET and SPECT reversible radiotracers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300790

Receptor affinity and pharmacological potency of a series of narcotic analgesic, anti-diarrheal and neuroleptic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300790

Molecular docking reveals a novel binding site model for fentanyl at the mu-opioid receptor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300790

Effect of naltrexone on alcohol "high" in alcoholics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300790

Naltrexone in the treatment of alcohol dependence

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300790

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1038/SJ.NPP.1300790

1 reference

Dimensions Publication ID

30 July 2017

1016493335

0 references

1 reference